“These complications have a direct impact on the morbidity and mortality experienced by H SCT survivors. Two-thirds of HSCT survivors develop at least one chronic health condition; while a fifth develop severe…”
Hi David, I had multiple myeloma diagnosis 2 years ago, low risk but 70% plasma cells in my bone marrow. Have tried almost everything I have read short of conventional treatment.
Still progressing but slowly. Slightly anemic but no other symptoms, Started RVD induction and scheduled for Transplant for now. I’m interested in anything I can do that does not interfere with treatment since I have committed to go this route. I would like to learn about the diet as well as supplement interactions. Keith
According to research, vitamin C and green tea (EGCG) reduce the efficacy of velcade (bortezomib). If you are taking either of those as supplements or drinking green tea or eating citrus fruits, simply don’t eat or drink either the day before taking velcade or the day after you’ve taken velcade.
On the plus side, there are a host of nutritional supplements that have been shown by research to enhance the efficacy of
- Revlimid (lenalidomide)
- Velcade (bortezomib)
It is your call or course, but if you are low risk (no genetic abnormalities) multiple myeloma diagnosis, in my experience, the standard-of-care (SOC) therapy plan for MM that you outline is too much toxicity.
Yes, I think it makes sense to undergo enough RVD (induction therapy) so that you can stabilize your MM diagnosis. But once you have achieved remission (MRD, sCR, CR, VGPR), I think you should discontinue chemo and let your body health. Your non-conventional nutrition and supplementation will help you at this point.
I will link two important studies below. These studies document two things. First, according to research, only a small portion of the youngest, healthiest, low risk, MM diagnosis patients can achieve a long progression-free survival (PFS- first remission).
Second, those MM patients that undergo an ASCT experience a host of long-term and late stage side effects leading to a lifetime of pain and suffering.
Please read the studies linked below and let me know if you have any questions.
Hang in there,
- MM Survivor
- MM Cancer Coach
- Director PeopleBeatingCancer
“Between January 1994 and December 2010, 406 consecutive newly diagnosed MM patients received first line therapy in the Department of Clinical Therapeutics (Athens, Greece).
All patients had symptomatic disease, based on the IMWG criteria of that period (at least one CRAB symptom to start anti-myeloma therapy). Thirty-six (8.8%; 23M/13F) patients achieved a PFS of at least 7 years (long PFS group) after frontline treatment.
The median PFS of these 36 patients is 10 years, while the other patients had a median PFS of 22 months…
In conclusion, our study in an unselected group of patients, the majority of whom did not participate in clinical trials, showed that 9% of patients with newly diagnosed myeloma experience prolonged PFS of more than 7 years (median: 10 years) even in the era of CC or first-generation novel agents.
These patients have:
- low risk disease,
- mainly of ISS-1 or -2,
- no high-risk cytogenetics,
- no or mild renal impairment,
- and achieve deep responses after ASCT
“However, hematopoietic stem cell transplantation (HSCT) survivors are at risk of developing long-term complications, such as
- musculoskeletal disorders,
- cardiopulmonary compromise and
- subsequent malignancies.
These complications have a direct impact on the morbidity and mortality experienced by HSCT survivors. Two-thirds of HSCT survivors develop at least one chronic health condition; while a fifth develop severe or life-threatening conditions. HSCT patients who have survived for at least 5 years post-transplantation are at a fourfold to ninefold increased risk of late mortality for as long as 30 years from HSCT, producing an estimated 30% lower life expectancy compared with the general population…